Predicting Weight Loss After Pharmacological or Surgical Treatment in Patients With Obesity

NCT07402031 | Recruiting

• 1 other identifier: TCAPrediBaria
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

As with other nutritional strategies, the clinical response to bariatric surgery can be highly variable, with weight regain being a frequent occurrence. Recent evidence on anti-obesity medication indicate similar inter-individual variability in clinical response. Among multiples factors, co-occurrence of eating disorders such as binge eating disorder has been implicated in insufficient clinical response. Improving our ability to predict how patients will respond to obesity treatment is necessary in order to tailor the care pathways we offer. The mechanisms involved in disturbances of eating behaviour before and after surgery remain largely unknown. This study aims to identify the predictive factors of weight loss after pharmacological or surgical treatment, as well as the cognitive and biological mechanisms that mediate this effect.

Conditions

Obesity & Overweight

Outcome Measures

Primary Outcomes (1)

• Correlation between weight loss after treatment and clinical, neuropsychological and biological parameters.

  The percentage of excessive weight loss after treatment will be correlated with * Clinical parameters (Binge Eating Scale and modified Yale Food Addiction Scale 2.0) * Neuropsychological parameter (Barratt Impulsivness Scale and Trail Making Test) * Biological parameters

  Throughout the entire study, aproximately during 5 years

Secondary Outcomes (11)

• Binge Eating Disorder.

  Throughout the entire study, aproximately during 5 years

• Food Addiction.

  Throughout the entire study, aproximately during 5 years

• Eating attitudes

  Throughout the entire study, aproximately during 5 years

• Cognitive flexibility.

  Throughout the entire study, aproximately during 5 years

• Impulsivity.

  Throughout the entire study, aproximately during 5 years

Other Outcomes (3)

• Sociodemographic data

  Once at inclusion

• Medical history

  Once at inclusion

• Childhood Trauma.

  Once at inclusion

Interventions

Pharmacological or surgical treament of obesity PROCEDURE

Longitudinal follow-up of participants who initiate an anti-obesity medication or whose application for bariatric surgery was accepted. It will combine anthropometric, clinical, neuropsychological and biological measurements taken at various timepoints. Participants will be asked to complete a set of online questionnaires and data will be recorded anonymously. Biological samples will be collected at various time points.

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Participants initiating an anti-obesity medication or candidates for bariatric surgery once its indication has been validated by a multidisciplinary committee, following medical, nutritional and psychological evaluations.

You may qualify if:

• Age between 18 and 65 years
• Obesity, with bariatric surgery indicated after a multidisciplinary evaluation in case of surgical treatment.
• Good physical and mental health, enabling informed consent.
• French speaker

You may not qualify if:

• Legal protection
• Pregnancy or breastfeeding
• History of bariatric surgery (except gastric banding, provided it was removed more than five years ago).
• Acute or progressive chronic disease
• Alcohol consumption of more than 20 g/day
• Inflammatory bowel disease;
• Digestive autonomic diabetic neuropathy.
• Consumption of dietary supplements (stanols, probiotics, prebiotics or omega-3).
• Following a vegan or gluten-free diet or being lactose intolerant.
• Fibre consumption \>30 g/day
• Recent change in antidiabetic medication within the past 3 months.

Sponsors & Collaborators

• Université Catholique de Louvain: lead

Study Sites (1)

Cliniques Universitaires Saint-Luc

Brussels, Brussels Capital, 1200, Belgium

RECRUITING

MeSH Terms

Conditions

Obesity; Overweight

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Amandine Everard, Professor

  Université Catholique de Louvain

  STUDY DIRECTOR

Central Study Contacts

Pr Amandine Everard, Professor

CONTACT

+ 32 (0)2 436 22 10; amandine.everard@uclouvain.be

Yannick Deswysen, Doctor

CONTACT

+ 32 2 764 22 13; yannick.deswysen@saintluc.uclouvain.be

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 13, 2026
• First Posted: February 11, 2026
• Study Start: May 5, 2026
• Primary Completion (Estimated): June 1, 2032
• Study Completion (Estimated): January 1, 2036
• Last Updated: May 14, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)